LENZ Therapeutics, Inc. (NASDAQ:LENZ) today announced that it has submitted a Marketing Authorization Application (MAA) to the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for the review and approval of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia in adults. Since receiving U.S. Food and Drug Administration (FDA) approval in July 2025, LENZ has moved rapidly to expand global access to VIZZ, with submission of the MAA in the United Kingdom representing the sixth ex-U.S. regulatory submission for VIZZ.